Pulmonary Arterial Hypertension Global Market Report 2025

Global Pulmonary Arterial Hypertension Market Report 2024

Pulmonary Arterial Hypertension Global Market Report 2025 – By Drug Class (Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, SGC Stimulators), By Route of Administration (Oral, Intravenous/ subcutaneous, Inhalational), By Distribution channel (Retail, Online) – Market Size, Trends, And Global Forecast 2025-2034

Name: Pulmonary Arterial Hypertension Global Market Report 2025
Creator: The Business Research Company
License: https://www.thebusinessresearchcompany.com/privacy-policy

Pulmonary Arterial Hypertension Global Market Report 2025

Report Price : $4490.00 | Pages : 200 | Published : January 2025 | Delivery Time: 2-3 business days | Format : pdf

Purchase Options

Request a Sample

Request For Discount

Customise Your Report

Item added to cart!

Request For Proposal

Request For Regional Data

FAQs

Need assistance or more information before the purchase?

Enquire Before Buying

Pulmonary Arterial Hypertension Global Market Report 2024

Proud Members Of

Pulmonary Arterial Hypertension Market Definition

Pulmonary arterial hypertension refers to a form of excessive blood pressure that harms the right side of the heart and the arteries in the lungs. The lungs' artery walls become constricted and rigid due to this long-lasting, incurable condition. The pulmonary arterial hypertension drugs relax the muscles in the walls of the blood vessels, increase the blood flow through the lungs, or reverse the effect of the substance in the walls of blood vessels that causes them to narrow.

The main types of pulmonary arterial hypertension drug classes are endothelin receptor antagonists (ERAS), PDE-5 inhibitors, prostacyclin and prostacyclin analogs, and SGC stimulators. Endothelin receptor antagonists (ERAs) are a form of targeted medication that is used to treat pulmonary hypertension in patients (PH). Targeted medicines can help to reduce the course of PH and potentially reverse some of the heart and lung damage. The drugs are administered through oral, intravenous/subcutaneous, and inhalational modes and distributed through retail and online channels.

Pulmonary Arterial Hypertension Market Segmentation

The pulmonary arterial hypertension market covered in this report is segmented –

1) By Drug Class: Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, SGC Stimulators

2) By Route Of Administration: Oral, Intravenous Or subcutaneous, Inhalational

3) By Distribution channel: Retail, Online

Subsegments:

1) By Endothelin Receptor Antagonists (ERAs): Bosentan, Ambrisentan, Macitentan

2) By PDE-5 Inhibitors: Sildenafil, Tadalafil

3) By Prostacyclin And Prostacyclin Analogs: Epoprostenol, Treprostinil, Iloprost

4) By SGC Stimulators: Riociguat

Pulmonary Arterial Hypertension Market Size and growth rate 2025 to 2029: Graph

Pulmonary Arterial Hypertension Market Size 2025 And Growth Rate

The pulmonary arterial hypertension market size has grown strongly in recent years. It will grow from $8.47 billion in 2024 to $9.24 billion in 2025 at a compound annual growth rate (CAGR) of 9.1%. The growth in the historic period can be attributed to increased awareness and diagnosis of pulmonary arterial hypertension (PAH), increased healthcare expenditure, growth in aging population, expansion of pulmonary arterial hypertension treatment options, rise in research and development activities in pulmonary hypertension.

Pulmonary Arterial Hypertension Market Growth Forecast

The pulmonary arterial hypertension market size is expected to see strong growth in the next few years. It will grow to $12.97 billion in 2029 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to adoption of novel therapies for pulmonary arterial hypertension, increased focus on early detection and diagnosis, growing pipeline of PAH drugs and therapies, integration of precision medicine in PAH treatment, expansion of healthcare infrastructure in emerging markets. Major trends in the forecast period include advancements in medical imaging and diagnostic technologies, collaboration and partnerships for drug development, patient-centric approaches in pulmonary arterial hypertension management, increased use of combination therapy.

Book your 30 minutes free consultation with our research experts

Pulmonary Arterial Hypertension Market Driver: Elevated Prevalence Of Pulmonary Arterial Hypertension (PAH) Driving Market Growth

The increasing prevalence of pulmonary arterial hypertension (PAH) disease is contributing to the growth of the pulmonary arterial hypertension market. The increasing prevalence of PAH diseases and the related hospitalization of patients for treatment is expected to boost the demand for relevant drugs during the forecast period. According to a study published by the National Organization for Rare Disorders, Inc., new cases of PAH are estimated to occur in one to two individuals per million each year in the USA, which equates to 500–1000 new cases each year, and Europe is expected to have similar incidence rates.

Pulmonary Arterial Hypertension Market Driver: Elevated Clinical Trials Activity Fuels Growth In The Pulmonary Arterial Hypertension Market

Th rising clinical trials for drug development is expected to propel the growth of the pulmonary arterial hypertension market going forward. Clinical trials for drug development are research studies conducted to evaluate the safety, efficacy, and potential side effects of a new drug or treatment in humans. Clinical trials for drug development of pulmonary arterial hypertension can lead to the development of new and more effective treatments, improving the quality of life, enhancing safety and efficacy, and early access, and helping identify cost-effective treatments. For instance, in May 2023, according to Xtalks, a Canada-based company specializing in providing life science webinars and virtual events, there are 452,604 clinical studies that have been registered on ClinicalTrials. gov as of May 17, 2023. 64,838 studies out of the total number that have been registered are actively seeking participants which is an increase of 365,000 registered trials in 2021. Therefore, the rising clinical trials for drug development is driving the growth of the pulmonary arterial hypertension market.

Global Pulmonary Arterial Hypertension Market Major Players

Major companies operating in the pulmonary arterial hypertension market include United Therapeutics Corporation, Acceleron Pharma Inc., Actelion Pharmaceuticals US Inc., Bayer AG, Eli Lilly and Company, Gilead Sciences Inc., GlaxoSmithKline plc, Johnson & Johnson, Liquidia Technologies Inc., Lupin Pharmaceuticals Inc., Natco Pharma Ltd., Pfizer Inc., Sandoz AG, Teva Pharmaceutical Industries Ltd., Zydus Pharmaceutical USA Inc., Allegheny Health Network, Cedars-Sinai Medical Center, Cleveland Clinic, Houston Methodist Hospital, Johns Hopkins Medicine, Massachusetts General Hospital, Mayo Clinic, MedStar Heart & Vascular Institute, National Jewish Health, NewYork-Presbyterian Hospital, Ochsner Medical Center, Royal Brompton & Harefield NHS Foundation Trust, Rush University Medical Center, Stanford Health Care, Swedish Medical Center, Temple University Hospital, University of California Health.

Global Pulmonary Arterial Hypertension Market Trend: Merck & Co. Introduces Innovative FDA-Approved Therapy For Pulmonary Arterial Hypertension

Major companies operating in the pulmonary arterial hypertension market are innovating advanced products, such as Winrevair, to improve treatment options and outcomes for patients suffering from this serious condition. For instance, in March 2024, Merck & Co. Inc., a US-based multinational pharmaceutical company launched Winrevair for the treatment of adults with pulmonary arterial hypertension. Winrevair is the first Food and Drug Administration (FDA), a US-based federal agency-approved therapy targeting activin signaling for pulmonary arterial hypertension (PAH). This innovative treatment works by restoring the balance between pro- and anti-proliferative signals, which helps regulate the vascular cell proliferation associated with PAH. As a result, it introduces a new class of therapy for this condition.

Global Pulmonary Arterial Hypertension Market Trend: Johnson & Johnson Launches OPSYNVI To Enhance Treatment Options For Pulmonary Arterial Hypertension

Major companies operating in the pulmonary arterial hypertension market are innovating advanced products, such as OPSYNVI, to provide improved treatment options that enhance patient outcomes and quality of life for individuals suffering from this serious condition. For instance, In March 2024, Johnson & Johnson, a US-based multinational company specializing in pharmaceuticals, biotechnology, and medical technologies, launched OPSYNVI for the chronic treatment of adults with pulmonary arterial hypertension. OPSYNVI can be used for patients with pulmonary arterial hypertension (PAH) who are either new to treatment or already taking an endothelin receptor antagonist (ERA) or PDE5 inhibitor, or both. It is also suitable for those on stable doses of macitentan 10 mg and tadalafil 40 mg, administered as separate tablets.

Pulmonary Arterial Hypertension Market Merger And Acquisition: Gossamer Bio Partners With Chiesi Farmaceutici To Advance Treatment For Pulmonary Arterial Hypertension

In May 2024, Gossamer Bio, US-based biopharmaceutical company that provides treatment for Pulmonary Arterial Hypertension (PAH) partnered with Chiesi Farmaceutici S.p.A. With this partnership, both companies are combining their strengths to improve the treatment of pulmonary arterial hypertension (PAH) and speed up the development of products for pulmonary hypertension linked to interstitial lung disease (PH-ILD). Chiesi Farmaceutici S.p.A, Italy-based pharmaceutical company

Regional Outlook For The Global Pulmonary Arterial Hypertension Market

North America was the largest region in the pulmonary arterial hypertension market in 2024. The regions covered in the pulmonary arterial hypertension market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the pulmonary arterial hypertension market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

What Defines the Pulmonary Arterial Hypertension Market?

The pulmonary arterial hypertension market includes revenues earned by entities by idiopathic, heritable, and drug and toxin-induced. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Pulmonary Arterial Hypertension Industry?

The pulmonary arterial hypertension market research report is one of a series of new reports from The Business Research Company that provides pulmonary arterial hypertension market statistics, including pulmonary arterial hypertension industry global market size, regional shares, competitors with a pulmonary arterial hypertension market share, detailed pulmonary arterial hypertension market segments, market trends and opportunities, and any further data you may need to thrive in the pulmonary arterial hypertension industry. This pulmonary arterial hypertension market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Pulmonary Arterial Hypertension Market Report Forecast Analysis

Report Attribute	Details
Market Size Value In 2025	$9.24 billion
Revenue Forecast In 2034	$12.97 billion
Growth Rate	CAGR of 8.8% from 2025 to 2034
Base Year For Estimation	2024
Actual Estimates/Historical Data	2019-2024
Forecast Period	2025 - 2029 - 2034
Market Representation	Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered	1) By Drug Class: Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, SGC Stimulators 2) By Route Of Administration: Oral, Intravenous Or subcutaneous, Inhalational 3) By Distribution channel: Retail, Online Subsegments: 1) By Endothelin Receptor Antagonists (ERAs): Bosentan, Ambrisentan, Macitentan 2) By PDE-5 Inhibitors: Sildenafil, Tadalafil 3) By Prostacyclin And Prostacyclin Analogs: Epoprostenol, Treprostinil, Iloprost 4) By SGC Stimulators: Riociguat
Regional Scope	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope	The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled	United Therapeutics Corporation, Acceleron Pharma Inc., Actelion Pharmaceuticals US Inc., Bayer AG, Eli Lilly and Company, Gilead Sciences Inc., GlaxoSmithKline plc, Johnson & Johnson, Liquidia Technologies Inc., Lupin Pharmaceuticals Inc., Natco Pharma Ltd., Pfizer Inc., Sandoz AG, Teva Pharmaceutical Industries Ltd., Zydus Pharmaceutical USA Inc., Allegheny Health Network, Cedars-Sinai Medical Center, Cleveland Clinic, Houston Methodist Hospital, Johns Hopkins Medicine, Massachusetts General Hospital, Mayo Clinic, MedStar Heart & Vascular Institute, National Jewish Health, NewYork-Presbyterian Hospital, Ochsner Medical Center, Royal Brompton & Harefield NHS Foundation Trust, Rush University Medical Center, Stanford Health Care, Swedish Medical Center, Temple University Hospital, University of California Health.
Customization Scope	Request for Sample
Pricing And Purchase Options	Explore Purchase Options

1. Executive Summary

2. Pulmonary Arterial Hypertension Market Characteristics

3. Pulmonary Arterial Hypertension Market Trends And Strategies

4. Pulmonary Arterial Hypertension Market- Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Pulmonary Arterial Hypertension Growth Analysis And Strategic Analysis Framework

5.1. Global Pulmonary Arterial Hypertension PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Pulmonary Arterial Hypertension Market Growth Rate Analysis

5.4. Global Pulmonary Arterial Hypertension Historic Market Size and Growth, 2019- 2024, Value ($ Billion)

5.5. Global Pulmonary Arterial Hypertension Forecast Market Size and Growth, 2024- 2029, 2034F, Value ($ Billion)

5.6. Global Pulmonary Arterial Hypertension Total Addressable Market (TAM)

6. Pulmonary Arterial Hypertension Market Segmentation

6.1. Global Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Endothelin Receptor Antagonists (ERAs)

PDE-5 Inhibitors

Prostacyclin and Prostacyclin Analogs

SGC Stimulators

6.2. Global Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Oral

Intravenous/ subcutaneous

Inhalational

6.3. Global Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Retail

Online

6.4. Global Pulmonary Arterial Hypertension Market, Sub-Segmentation Of Endothelin Receptor Antagonists (ERAs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Bosentan

Ambrisentan

Macitentan

6.5. Global Pulmonary Arterial Hypertension Market, Sub-Segmentation Of PDE-5 Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Sildenafil

Tadalafil

6.6. Global Pulmonary Arterial Hypertension Market, Sub-Segmentation Of Prostacyclin And Prostacyclin Analogs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Epoprostenol

Treprostinil

Illoprost

6.7. Global Pulmonary Arterial Hypertension Market, Sub-Segmentation Of SGC Stimulators, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Riociguat

7. Pulmonary Arterial Hypertension Market Regional And Country Analysis

7.1. Global Pulmonary Arterial Hypertension Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Pulmonary Arterial Hypertension Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Pulmonary Arterial Hypertension Market

8.1. Asia-Pacific Pulmonary Arterial Hypertension Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Pulmonary Arterial Hypertension Market

9.1. China Pulmonary Arterial Hypertension Market Overview

9.2. China Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Pulmonary Arterial Hypertension Market

10.1. India Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Pulmonary Arterial Hypertension Market

11.1. Japan Pulmonary Arterial Hypertension Market Overview

11.2. Japan Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Pulmonary Arterial Hypertension Market

12.1. Australia Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Pulmonary Arterial Hypertension Market

13.1. Indonesia Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Pulmonary Arterial Hypertension Market

14.1. South Korea Pulmonary Arterial Hypertension Market Overview

14.2. South Korea Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Pulmonary Arterial Hypertension Market

15.1. Western Europe Pulmonary Arterial Hypertension Market Overview

15.2. Western Europe Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Pulmonary Arterial Hypertension Market

16.1. UK Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Pulmonary Arterial Hypertension Market

17.1. Germany Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Pulmonary Arterial Hypertension Market

18.1. France Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Pulmonary Arterial Hypertension Market

19.1. Italy Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Pulmonary Arterial Hypertension Market

20.1. Spain Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Pulmonary Arterial Hypertension Market

21.1. Eastern Europe Pulmonary Arterial Hypertension Market Overview

21.2. Eastern Europe Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Pulmonary Arterial Hypertension Market

22.1. Russia Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Pulmonary Arterial Hypertension Market

23.1. North America Pulmonary Arterial Hypertension Market Overview

23.2. North America Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Pulmonary Arterial Hypertension Market

24.1. USA Pulmonary Arterial Hypertension Market Overview

24.2. USA Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Pulmonary Arterial Hypertension Market

25.1. Canada Pulmonary Arterial Hypertension Market Overview

25.2. Canada Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Pulmonary Arterial Hypertension Market

26.1. South America Pulmonary Arterial Hypertension Market Overview

26.2. South America Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Pulmonary Arterial Hypertension Market

27.1. Brazil Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Pulmonary Arterial Hypertension Market

28.1. Middle East Pulmonary Arterial Hypertension Market Overview

28.2. Middle East Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Pulmonary Arterial Hypertension Market

29.1. Africa Pulmonary Arterial Hypertension Market Overview

29.2. Africa Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Pulmonary Arterial Hypertension Market Competitive Landscape And Company Profiles

30.1. Pulmonary Arterial Hypertension Market Competitive Landscape

30.2. Pulmonary Arterial Hypertension Market Company Profiles

30.2.1. Siemens AG Overview, Products and Services, Strategy and Financial Analysis

30.2.2. Hitachi Ltd. Overview, Products and Services, Strategy and Financial Analysis

30.2.3. Wabtec Corporation Overview, Products and Services, Strategy and Financial Analysis

30.2.4. DXC Technology Company Overview, Products and Services, Strategy and Financial Analysis

30.2.5. L&T Technology Services Limited Overview, Products and Services, Strategy and Financial Analysis

31. Pulmonary Arterial Hypertension Market Other Major And Innovative Companies

31.1. SAP SE

31.2. Capgemini SE

31.3. Cisco Systems Inc.

31.4. Accenture plc

31.5. Atkins Global

31.6. Trimble Inc.

31.7. WSP Global Inc.

31.8. Tego Inc.

31.9. KONUX GmbH

31.10. Oxplus B. V.

31.11. Bentley Systems, Incorporated

31.12. Trapeze Group

31.13. Uptake Technologies Inc.

31.14. Huawei Technologies Co. Ltd.

31.15. Cyient Limited

32. Global Pulmonary Arterial Hypertension Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Pulmonary Arterial Hypertension Market

34. Recent Developments In The Pulmonary Arterial Hypertension Market

35. Pulmonary Arterial Hypertension Market High Potential Countries, Segments and Strategies

35.1 Pulmonary Arterial Hypertension Market In 2029- Countries Offering Most New Opportunities

35.2 Pulmonary Arterial Hypertension Market In 2029- Segments Offering Most New Opportunities

35.3 Pulmonary Arterial Hypertension Market In 2029- Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

Table 1: Global Historic Market Growth, 2019-2024, $ Billion

Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Table 3: Global Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 4: Global Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 5: Global Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 6: Global Pulmonary Arterial Hypertension Market, Sub-Segmentation Of Endothelin Receptor Antagonists (ERAs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 7: Global Pulmonary Arterial Hypertension Market, Sub-Segmentation Of PDE-5 Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 8: Global Pulmonary Arterial Hypertension Market, Sub-Segmentation Of Prostacyclin And Prostacyclin Analogs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 9: Global Pulmonary Arterial Hypertension Market, Sub-Segmentation Of SGC Stimulators, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 10: Global Pulmonary Arterial Hypertension Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 11: Global Pulmonary Arterial Hypertension Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 12: Asia-Pacific, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 13: Asia-Pacific, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 14: Asia-Pacific, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 15: China, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 16: China, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 17: China, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 18: India, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 19: India, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 20: India, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 21: Japan, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 22: Japan, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 23: Japan, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 24: Australia, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 25: Australia, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 26: Australia, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 27: Indonesia, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 28: Indonesia, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 29: Indonesia, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 30: South Korea, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 31: South Korea, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 32: South Korea, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 33: Western Europe, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 34: Western Europe, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 35: Western Europe, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 36: UK, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 37: UK, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 38: UK, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 39: Germany, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 40: Germany, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 41: Germany, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 42: France, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 43: France, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 44: France, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 45: Italy, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 46: Italy, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 47: Italy, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 48: Spain, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 49: Spain, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 50: Spain, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 51: Eastern Europe, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 52: Eastern Europe, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 53: Eastern Europe, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 54: Russia, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 55: Russia, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 56: Russia, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 57: North America, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 58: North America, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 59: North America, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 60: USA, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 61: USA, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 62: USA, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 63: Canada, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 64: Canada, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 65: Canada, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 66: South America, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 67: South America, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 68: South America, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 69: Brazil, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 70: Brazil, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 71: Brazil, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 72: Middle East, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 73: Middle East, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 74: Middle East, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 75: Africa, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 76: Africa, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 77: Africa, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 78: Siemens AG Financial Performance

Table 79: Hitachi Ltd. Financial Performance

Table 80: Wabtec Corporation Financial Performance

Table 81: DXC Technology Company Financial Performance

Table 82: L&T Technology Services Limited Financial Performance

List Of Figures

Figure 1: Global Historic Market Growth, 2019-2024, $ Billion

Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Figure 3: Global Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 4: Global Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 5: Global Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 6: Global Pulmonary Arterial Hypertension Market, Sub-Segmentation Of Endothelin Receptor Antagonists (ERAs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 7: Global Pulmonary Arterial Hypertension Market, Sub-Segmentation Of PDE-5 Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 8: Global Pulmonary Arterial Hypertension Market, Sub-Segmentation Of Prostacyclin And Prostacyclin Analogs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 9: Global Pulmonary Arterial Hypertension Market, Sub-Segmentation Of SGC Stimulators, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 10: Global Pulmonary Arterial Hypertension Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 11: Global Pulmonary Arterial Hypertension Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 12: Asia-Pacific, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 13: Asia-Pacific, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 14: Asia-Pacific, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 15: China, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 16: China, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 17: China, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 18: India, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 19: India, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 20: India, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 21: Japan, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 22: Japan, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 23: Japan, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 24: Australia, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 25: Australia, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 26: Australia, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 27: Indonesia, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 28: Indonesia, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 29: Indonesia, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 30: South Korea, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 31: South Korea, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 32: South Korea, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 33: Western Europe, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 34: Western Europe, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 35: Western Europe, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 36: UK, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 37: UK, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 38: UK, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 39: Germany, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 40: Germany, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 41: Germany, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 42: France, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 43: France, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 44: France, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 45: Italy, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 46: Italy, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 47: Italy, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 48: Spain, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 49: Spain, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 50: Spain, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 51: Eastern Europe, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 52: Eastern Europe, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 53: Eastern Europe, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 54: Russia, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 55: Russia, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 56: Russia, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 57: North America, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 58: North America, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 59: North America, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 60: USA, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 61: USA, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 62: USA, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 63: Canada, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 64: Canada, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 65: Canada, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 66: South America, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 67: South America, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 68: South America, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 69: Brazil, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 70: Brazil, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 71: Brazil, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 72: Middle East, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 73: Middle East, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 74: Middle East, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 75: Africa, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 76: Africa, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 77: Africa, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 78: Siemens AG Financial Performance

Figure 79: Hitachi Ltd. Financial Performance

Figure 80: Wabtec Corporation Financial Performance

Figure 81: DXC Technology Company Financial Performance

Figure 82: L&T Technology Services Limited Financial Performance

Latest Cell Therapy Market Growth Study 2022-2026 By The Business Research Company

Global Gene Therapy Market 2022 – Market Opportunities And Strategies

The Microbiome Market Share, Market Size, And Growth Rate 2022

The Plasma Fractionation Market Share, Market Size, And Growth Rate 2022

The Business Research Company offers the plasma fractionation market research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the gastric cancer drugs market research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the anti-asthmatic and copd drugs market research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the dry eye medication market research report 2022 with industry size, share, segments and market growth

Respiratory Devices And Equipment (Diagnostic) Global Market Report 2025 – By Product (Instruments And Devices, Assays And Reagents), By Test Type (Traditional Diagnostic Tests, Mechanical Tests, Imaging Tests, Molecular Diagnostic Tests), By Disease Type (Chronic Obstructive Pulmonary Disease, Lung Cancer, Asthma, Tuberculosis, Other Diseases), By End User (Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories, Other End Users) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Anti-Hypertensive Drugs Global Market Report 2025 – By Therapeutics (Diuretics, Angiotensin Receptor Blockers (ARBs), Angiotensin Converting Enzyme (ACE) Inhibitors, Beta Blockers, Alpha Blockers, Calcium Channel Blockers, Renin Inhibitors, Vasodilators), By Disease Source (Primary Hypertension, Secondary Hypertension), By End Users (Hospitals, Clinics, Homecare) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Anticoagulants Global Market Report 2025 – By Drug Class (Factor Xa Inhibitor, Heparin And LMWH, Vitamin K Antagonist, Other Drug Classes), By Route Of Administration (Oral Anticoagulant, Injectable Anticoagulant), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By Application (Venous Thromboembolism, Atrial Fibrillation Or Flutter, Coronary Artery Disease, Other Applications), By End User (Hospitals, Homecare, Specialty Centers, Other End-Users) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Cardiovascular Medical Lasers Global Market Report 2025 – By Type (Excimer Laser, Carbon Dioxide Laser), By Application (Laser Vascular Anastomosis, Transmyocardial Laser Revascularization, Laser Angioplasty For Peripheral Arterial Diseases), By End Use (Hospitals, Specialty Clinics, Ambulatory Surgery Centers) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Bioabsorbable Stents Global Market Report 2025 – By Product Type (Polymer-based Bioabsorbable Stents, Metal-based Bioabsorbable Stents), By Absorption Rate (Slow- absorption stents, Fast- absorption Stents), By Applications (Coronary Artery Diseases, Peripheral Artery Diseases) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Blood Transfusion Diagnostics Global Market Report 2025 – By Type (Instruments and Kits, Reagents, Other Types), By Technology (Western Blot, ELISA, Nucleic Acid Amplification, Fluorescence assay, Rapid Test), By Application (Blood Grouping, Disease Screening), By End User (Hospitals, Diagnostic Laboratories, Blood Banks, Plasma Fractionation Companies) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Blood Culture Tests Global Market Report 2025 – By Method (Conventional/Manual Methods, Automated Methods), By Product (Consumables, Instruments, Software and Services), By Technology (Culture-Based Technology, Molecular Technologies, Microarrays, PCR (Polymerase Chain Reaction), PNA-FiSH (Peptide Nucleic Acid – Fluorescent in Situ Hybridization), Proteomics Technology), By Application (Bacteremia, Fungemia, Mycobacterial Detection), By End User (Hospital Laboratories, Reference Laboratories, Academic Research Laboratories, Other Laboratories) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Blood Collection Devices Global Market Report 2025 – By Type (Blood Collection Tubes, Lancet, Micro Container Tubes, Warming Devices), By Method (Manual Blood Collection, Automatic Blood Collection), By Material (Glass, Stainless Steel, Plastic), By End User (Hospitals, Blood Donation Centers, Diagnostic Center, Other End Users) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Frequently Asked Questions

What is the definition of the pulmonary arterial hypertension market?

How will the pulmonary arterial hypertension market drivers and restraints affect the pulmonary arterial hypertension market dynamics? What forces will shape the pulmonary arterial hypertension industry going forward?

The pulmonary arterial hypertension market major growth driver - Elevated Prevalence Of Pulmonary Arterial Hypertension (PAH) Driving Market Growth. For further insights on the pulmonary arterial hypertension market, request a sample here

What is the forecast market size or the forecast market value of the pulmonary arterial hypertension market?

The pulmonary arterial hypertension market size has grown strongly in recent years. It will grow from $8.47 billion in 2024 to $9.24 billion in 2025 at a compound annual growth rate (CAGR) of 9.1%. The growth in the historic period can be attributed to increased awareness and diagnosis of pulmonary arterial hypertension (PAH), increased healthcare expenditure, growth in aging population, expansion of pulmonary arterial hypertension treatment options, rise in research and development activities in pulmonary hypertension. The pulmonary arterial hypertension market size is expected to see strong growth in the next few years. It will grow to $12.97 billion in 2029 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to adoption of novel therapies for pulmonary arterial hypertension, increased focus on early detection and diagnosis, growing pipeline of PAH drugs and therapies, integration of precision medicine in PAH treatment, expansion of healthcare infrastructure in emerging markets. Major trends in the forecast period include advancements in medical imaging and diagnostic technologies, collaboration and partnerships for drug development, patient-centric approaches in pulmonary arterial hypertension management, increased use of combination therapy. For further insights on the pulmonary arterial hypertension market, request a sample here

How is the pulmonary arterial hypertension market segmented?

The pulmonary arterial hypertension market is segmented
1) By Drug Class: Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, SGC Stimulators
2) By Route Of Administration: Oral, Intravenous Or subcutaneous, Inhalational
3) By Distribution channel: Retail, Online Subsegments:
1) By Endothelin Receptor Antagonists (ERAs): Bosentan, Ambrisentan, Macitentan
2) By PDE-5 Inhibitors: Sildenafil, Tadalafil
3) By Prostacyclin And Prostacyclin Analogs: Epoprostenol, Treprostinil, Iloprost
4) By SGC Stimulators: Riociguat For further insights on the pulmonary arterial hypertension market, request a sample here

Which region has the largest share of the pulmonary arterial hypertension market? What are the other regions covered in the report?

North America was the largest region in the pulmonary arterial hypertension market in 2024. The regions covered in the pulmonary arterial hypertension market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa For further insights on the pulmonary arterial hypertension market, request a sample here.

Who are the major players in the pulmonary arterial hypertension market?

What are the key trends in the pulmonary arterial hypertension market?

Major trend in the pulmonary arterial hypertension market - Merck & Co. Introduces Innovative FDA-Approved Therapy For Pulmonary Arterial Hypertension. For further insights on the pulmonary arterial hypertension market, request a sample here.

What are the major opportunities in the pulmonary arterial hypertension market? What are the strategies for the pulmonary arterial hypertension market?

For detailed insights on the major opportunities and strategies in the pulmonary arterial hypertension market, request a sample here.

How does the pulmonary arterial hypertension market relate to the overall economy and other similar markets?

For detailed insights on pulmonary arterial hypertension market's relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the pulmonary arterial hypertension industry?

For detailed insights on the mergers and acquisitions in the pulmonary arterial hypertension industry, request a sample here.

What are the key dynamics influencing the pulmonary arterial hypertension market growth? SWOT analysis of the pulmonary arterial hypertension market.

For detailed insights on the key dynamics influencing the pulmonary arterial hypertension market growth and SWOT analysis of the pulmonary arterial hypertension industry, request a sample here.